Background: This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC). We compared the recurrence-free survival (RFS) associated with CF plus Adriamycin (ACF) with that associated with CF plus docetaxel (DCF) to select an alternative regimen in a new phase III trial investigating the optimal neoadjuvant treatment of patients with ESCC. Results: Between October 2011 and October 2013, 162 patients at 10 institutions were enrolled in the study, all of whom were eligible and randomly assigned to the two groups (81 to the ACF group and 81 to the DCF group). The R0 resection rates for the ACF and DCF groups were equivalent (95.9% versus 96.2%, P ¼ 0.93). The 2-year RFS and overall survival rates for DCF versus ACF were 64.1% versus 42.9% (hazard ratio 0.53, 95% confidence interval 0.33-0.83, P ¼ 0.0057) and 78.6% versus 65.4% (P ¼ 0.08), respectively.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most refractory cancers [1] . To prolong the survival time of patients with resectable ESCC, multidisciplinary management, including chemoradiotherapy or chemotherapy as well as surgery, is used.
Most of the chemoradiotherapy or chemotherapy regimens used in the neoadjuvant setting for ESCC are based on doublets of cisplatin-fluorouracil (CF), because these agents are two of the most active single agents in squamous carcinomas and the effectiveness of this combination has been reported since the 1990s [2] . However, to further improve the dismal prognosis of these patients, it is necessary to further evaluate new regimens (triplets or additional biological therapies) that may increase the response rates before surgery and help with early control of the microscopic metastatic disease.
Recently, van Hagen et al. reported that neoadjuvant chemoradiotherapy that consisted of weekly administration of carboplatin and paclitaxel with concurrent radiotherapy improved overall survival (OS) compared with the surgery-alone group [hazard ratio (HR) 0.657, 95% confidence interval (CI) 0.495-0.871,
An alternative approach is neoadjuvant chemotherapy. Several trials indicated that neoadjuvant chemotherapy with CF is moderately effective, but the impact on survival is limited [4] [5] [6] [7] [8] . Some studies reported previously on the effectiveness of CF plus Adriamycin (ACF) as a neoadjuvant chemotherapy in patients with resectable ESCC [9] [10] [11] . The response rate of ACF was >40%, which is higher than that of CF. Another alternative regimen is CF plus docetaxel (DCF). Some trials have reported that DCF therapy to treat advanced and metastatic ESCC has a favorable objective response rate [12, 13] . We previously reported the effectiveness of DCF therapy in a phase I/II trial of patients with advanced and recurrent ESCC [14] . In addition, a few studies have indicated that preoperative DCF chemotherapy has a manageable toxicity profile and does not increase the frequency of complications associated with subsequent esophagectomies [15, 16] .
The present phase II trial was designed to compare preoperative chemotherapy with ACF versus DCF followed by surgery in patients with resectable ESCC in terms of the survival, curative resection rate, and response rate. Our objective was to determine whether these regimens could potentially be used as a standard neoadjuvant therapy for resectable ESCC.
Patients and methods

Patients
Patients were eligible if they had histologically proven squamous cell carcinoma of the thoracic esophagus, and were clinically confirmed, according to the seventh edition of the Tumor Node Metastasis Classification of the International Union Against Cancer (UICC-TNM) [17] , as T1-T4a, any N category, and M0 or M1LYM metastasis (confined to the supraclavicular lymph nodes) as evaluated by endoscopy; computed tomography of the neck, chest, and abdomen; and integrated fluorodeoxyglucose positron emission tomography/computed tomography. Endoscopic ultrasonography was used as an optional diagnostic method. Patients had to be 20 years old with an Eastern Cooperative Oncology Group performance status of 0-1, and no serious vital organ dysfunction (heart, pulmonary, liver, renal, and hematologic). All patients provided written informed consent before enrollment. The study protocol was approved by the institutional review board of each participating hospital. This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) of Japan (identification number UMIN000004555/000004616).
Study treatment
This study is an open-label, randomized phase II trial. Eligible patients were randomly assigned to either preoperative ACF chemotherapy followed by surgery (ACF group) or preoperative DCF chemotherapy followed by surgery (DCF group) at the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) Data Center. Random assignment was stratified according to the center and clinical N stage with the use of a least-squares method.
The ACF chemotherapy comprised two cycles of Adriamycin 35 mg/ m 2 and cisplatin 70 mg/m 2 as a 1-h intravenous infusion and fluorouracil (5-FU) 700 mg/m 2 /day as a continuous intravenous infusion for 7 days (days 1-7) every 4 weeks. The DCF chemotherapy comprised two cycles of docetaxel 70 mg/m 2 and cisplatin 70 mg/m 2 as a 1-h intravenous infusion and 5-FU 700 mg/m 2 /day as a continuous intravenous infusion for 5 days (days 1-5) every 3 weeks ( Figure 1 ). The dose reduction of chemotherapy was regulated over the course of a cycle as follows: if there was grade 4 leukopenia or neutropenia persisting for 3 days, febrile neutropenia, or grade 3 or higher thrombocytopenia, then cisplatin, 5-FU, and docetaxel or Adriamycin were reduced by 20% in the subsequent cycle. If there was grade 3 or higher stomatitis or diarrhea, then 5-FU was reduced by 20%. If there was grade 2 or higher nephrotoxicity, then cisplatin was reduced by 20%.
Surgery was scheduled after completion of the last cycle of chemotherapy in both groups (Figure 1 ). Surgery consisted of subtotal esophagectomy with two-or three-field lymphadenectomy. Esophagectomy through a right thoracotomy or video-assisted thoracoscopic surgery was acceptable, but transhiatal esophagectomy was not. The local surgeon decided on the surgical procedure, including the addition of a cervical lymphadenectomy, the reconstruction route, and organ reconstruction, in accordance with the site of the tumor and local practice.
Outcomes
The primary end point was recurrence-free survival (RFS). Secondary end points were OS, the R0 resection rate, histopathological response rate, postoperative complications, and safety. Disease recurrence was defined as locoregional (i.e. esophageal bed, anastomotic, or regional lymph nodes) or distant (i.e. non-regional lymph nodes except for supraclavicular lymph nodes or distant organs). The histopathological tumor response was evaluated according to the histological criteria of the Japanese Society for Esophageal Disease [18] . Briefly, evaluations were classified into five categories according to the proportion of tumor affected by degeneration or necrosis. Patients were seen every 3 months during the first 2 years after the date of random assignment, every 6 months for the next 3 years, and annually after 5 years.
Statistical analysis
We planned to enroll 160 patients for the primary analysis. Sample-size calculation was based on a two-sided log-rank test. One hundred and sixty patients were required to detect an increase in 2-year RFS from 42% in the ACF group to 60% in the DCF group, with 80% power to show a significant difference between groups and 10% type I error.
To compare proportions between treatments, the chi-square test for categorical data and the Student's t-test or Mann-Whitney U test for continuous data were used. The OS and RFS were calculated from the date of random assignment, estimated by the Kaplan-Meier method, and compared with the log-rank test on an intent-to-treat basis, and the corresponding HR was calculated with the 95% CI. The R0 resection rates were calculated in the resected patients alone.
Results
Patient characteristics
Between November 2010 and October 2012, 162 patients were enrolled from 10 institutions and randomly assigned to the two treatment groups: ACF (n ¼ 81) and DCF (n ¼ 81). The allocation of patients is shown in Figure 2 . All 162 patients (81 in ACF and 81 in DCF) were included in the intention-to-treat analysis. Baseline characteristics were generally well balanced between the treatment groups (Table 1) .
Treatment and compliance
In the ACF group, all 81 patients completed the first cycle of chemotherapy and 71 (88%) completed the second cycle. In the DCF group, 80 (99%) of 81 patients completed the first cycle of chemotherapy and 72 (90%) completed the second cycle. There were no treatment-related deaths before surgery. Surgery was carried out in 74 patients (91.4%) in the ACF group, with a median time from random assignment to surgery of 8.7 weeks (range 4.3-12 weeks). In the DCF group, 78 patients (96.3%) underwent surgery, with a median time from random assignment to surgery of 7.9 weeks (range 3.9-11 weeks). There were no significant differences in the length of hospital stay after surgery between the ACF and DCF groups (median; 29 versus 28 days, respectively). In-hospital death occurred in only one patient in the ACF group who died of cancer after an exploratory thoracotomy.
Histopathological tumor response and pathological stage
Among the 151 patients who underwent surgical resection, R0 resection rates for the ACF and DCF groups were equivalent (95.9% versus 96.2%, P ¼ 0.93) ( Table 2 ). The histological tumor response was assessed in all 151 resected main tumors. Of the 73 patients in the ACF group, the histological findings were grade 3: 0 patients, grade 2: 13, grade 1b: 14, grade 1a: 35, and grade 0: 11. Of the 75 patients in the DCF group, the histological findings were grade 3: 11 patients, grade 2: 22, grade 1b: 21, grade 1a: 22, and grade 0: 2. Thus, the effect of DCF on the histological findings of the main tumor was significantly higher than that of ACF (P < 0.0001). In addition, the pathological T stage was significantly earlier in the DCF group than in the ACF group (P ¼ 0.008). The median number of analyzed lymph nodes was 58 (range 16-139) in the ACF group and 56 (range 19-138) in the DCF group (P ¼ 0.8). The median number of lymph nodes showing disease invasion was 1 in both the ACF (range 0-19) and DCF (range 0-18) groups (P ¼ 0.69). There were no differences in the number of lymph node metastases or the pathological N stage between the groups. Overall, there were more cases of pathological stage II or lower disease in the DCF group (54%) than in the ACF group (44%), although the baseline clinical stage was similar between the groups. Pathological stage IV, due to subclavian lymph node metastasis, was half as frequent in the DCF group (8%) as in the ACF group (16%). Seven patients treated with DCF achieved a pathological complete response.
RFS andOS
Recurrent disease was observed in 72 patients (44.7%), 45 and 27 patients in the ACF and DCF groups, respectively. The frequency of recurrence was significantly higher in patients treated with ACF compared with DCF (P ¼ 0.008). At the time of analysis, the median follow-up was 34.7 months in the ACF group and 34.4 months in the DCF group. The 2-year RFS was 42.9% in the ACF group and 64.1% in the DCF group ( Figure 3A) . The RFS of patients in the DCF group was significantly better than that in the ACF group (HR 0.53, 95% CI 0.33-0.83, P ¼ 0.0057). The 2-year OS was 65.4% in the ACF group and 78.6% in the DCF group ( Figure 3B ) and this difference was not significant (P ¼ 0.08).
Discussion
Recently, chemoradiotherapy has become more commonly used as a neoadjuvant treatment of patients with resectable ESCC than chemotherapy, especially in Western countries [3, 6] . In Eastern Asia, neoadjuvant chemotherapy has generally been preferred to chemoradiotherapy for resectable ESCC, to ensure early control of the microscopic metastatic disease. Over the last few decades, the most common neoadjuvant chemotherapy regimen has been CF therapy.
In gastric and gastroesophageal adenocarcinoma, a few previous studies investigated whether CF plus epirubicin (ECF) was an effective alternative regimen compared with CF alone. They found higher response rates with ECF than CF [19, 20] ; moreover, perioperative ECF significantly improved OS. In addition, the results of the V-325 study and FLOT-4 trial confirmed the impact of docetaxel-containing triplets on pathological response in gastric and gastroesophageal adenocarcinoma [21, 22] . No trials have investigated the utility of an alternative regimen to CF as neoadjuvant chemotherapy in patients with resectable ESCC, despite the limited efficacy of CF. In this randomized trial of neoadjuvant chemotherapy in patients with resectable ESCC, we demonstrated an RFS benefit associated with the use of preoperative DCF followed by surgery compared with ACF followed by surgery. There was an estimated improvement of 20% in the 2-year RFS rate (66.3% in the DCF group versus 45.7% in the ACF group). This indicates that neoadjuvant DCF chemotherapy may be a promising treatment strategy for resectable ESCC. There were no differences between ACF and DCF with respect to OS. A possible reason for the similar OS result is that the follow-up period was too short to analyze this outcome. We did not report the long-term outcome in this study, because the median follow-up time for surviving patients was 34.5 months. We are currently conducting a follow-up study to assess the long-term prognosis.
To confirm our results and identify the optimal neoadjuvant therapy for resectable ESCC, a larger, phase III, randomized controlled trial is required to compare the efficacy of chemoradiotherapy, which is the current standard treatment, with DCF chemotherapy as a novel treatment. In conclusion, this study showed that DCF chemotherapy, compared with ACF, had a higher response rate and was associated with a prolonged RFS for patients with resectable ESCC. Thus, DCF chemotherapy may be a candidate neoadjuvant therapy for resectable ESCC.
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